MAPT and Cognitive impairment: More studies are required based on the usage of biomarker combinations, such as Aβ1-42 levels in combination with other markers (e.g., tau, phosphorylated tau, Aβ1-40, total Aβ) to develop CSF biochemical measurements allowing reliable diagnosis of AD versus other non-AD cognitive deficits.